Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
patient with aortic dilation and polycystic kidney disease
Original title: “A patient with aortic dilation and polycystic kidney disease.”
inflammation mediates the association of heavy metal exposures with kidney function evidence from a longitudinal study
Original title: “Inflammation mediates the association of heavy metal exposures with kidney function: Evidence from a longitudinal study.”
unveiling the silent burden high prevalence of occult nephropathies in radical nephrectomy specimens
Original title: “Unveiling the silent burden: high prevalence of occult nephropathies in radical nephrectomy specimens.”
In addition to delivering two approved medicines to Biogen’s portfolio, the acquisition of Apellis Pharmaceuticals will support the future launch of the pharma’s own kidney disease asset, currently in multiple Phase 3 trials.
Original title: “Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy”
Besting Vertex Pharmaceuticals’ kidney disease asset wasn’t enough to impress Wall Street, which appears to be “getting hung up” with the broad population data in Maze Therapeutics’ trial, according to Mizuho.
Original title: “Maze Loses Nearly a Third of Market Cap on Mixed Midstage Kidney Drug Data”
Alongside R1 Therapeutics, Mestag Therapeutics and iDEL Therapeutics also brought in money on Tuesday, helping to push their respective cancer portfolios forward.
Original title: “R1 Leads Busy Fundraising Day With $77.5M Series A Raise for Kidney Disease”
predictive factors of successful renal replacement therapy weaning deciding on patients orientations after renal replacement therapy stopping the doors study
Original title: “Predictive factors of successful renal replacement therapy weaning : Deciding On patients Orientations after Renal replacement therapy Stopping (The DOORS study).”
Sarepta has begun evaluating a regimen meant to lower the risk of liver damage in Elevidys recipients. Elsewhere, Inovio laid off staff and a Bayer kidney drug notched another trial victory.
Original title: “Sarepta tests new Elevidys safeguards; Sana advances diabetes cell therapy”
Company shares surged in after-market trading on results for a drug Vertex acquired in a multibillion-dollar deal and sees as having “best-in-class potential” in a competitive field.
Original title: “Vertex kidney disease drug hits mark in late-stage study”
case of autosomal dominant polycystic kidney disease with multiple bilateral spontaneous retroperitoneal hemorrhages
Original title: “A case of autosomal dominant polycystic kidney disease with multiple bilateral spontaneous retroperitoneal hemorrhages.”
inheritance puzzle a case of dual genetic kidney disease
Original title: “The Inheritance Puzzle: A Case of Dual Genetic Kidney Disease.”
kidney transplantation in advanced octogenarians the world s oldest kidney transplant recipient
Original title: “Kidney Transplantation in Advanced Octogenarians: The World's Oldest Kidney Transplant Recipient.”
The disease leads to the progressive growth of fluid-filled cysts in the kidneys, often resulting in kidney failure and other complications. This study marks the first in vivo evidence that base editing can be effective in kidney tissue, paving the way for similar approaches for other inherited kidney diseases. The research aligns with Mayo Clinic's Genesis initiative, focusing on preventing organ failure and restoring function through regenerative medicine and advanced therapies. Current treatments only slow disease progression without addressing the genetic root. Mayo Clinic's new approach uses CRISPR-based gene editing to precisely correct a DNA mutation in the PKD1 gene. Researchers developed two versions of a base editor, one for multiple organs and another specifically for kidney cells. This promising advancement directly targets the genetic mutation responsible for the condition, potentially altering the course of the disease. A single treatment of the gene therapy has shown to slow kidney cyst growth, improve heart and liver health, and extend survival in preclinical models. ROCHESTER, Minn. — Mayo Clinic researchers have made a significant breakthrough in treating autosomal dominant polycystic kidney disease (ADPKD) with a new gene-editing therapy.
Original title: “Mayo Clinic's gene therapy breakthrough targets most-common kidney disease | News | kimt.com”
CDC is teaming up with a broad coalition of kidney and dialysis organizations to reduce the number of bloodstream infections in dialysis patients. Each year, about 37,000 people get potentially deadly bloodstream infections related to their dialysis treatment.
Original title: “Dialysis organizations team up with CDC to protect patients - Press Release”